OBJECTIVE: Variants in the ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) gene have shown positive associations with diabetes and related phenotypes, including insulin resistance, metabolic syndrome, and type 1 diabetic nephropathy. Additionally, evidence for linkage for type 2 diabetes in African Americans was observed at 6q24-27, with the proximal edge of the peak encompassing the ENPP1 gene. Our objective was to comprehensively evaluate variants in ENPP1 for association with type 2 diabetic end-stage renal disease (ESRD). RESEARCH DESIGN AND METHODS: Forty-nine single nucleotide polymorphisms (SNPs) located in the coding and flanking regions of ENPP1 were genotyped in 577 African-American individuals with type 2 diabetic ESRD and 596 African-American control subjects. Haplotypic association and genotypic association for the dominant, additive, and recessive models were tested by calculating a chi(2) statistic and corresponding P value. RESULTS: Nine SNPs showed nominal evidence for association (P < 0.05) with type 2 diabetic ESRD in one or more genotypic model. The most significant associations were observed with rs7754586 (P = 0.003 dominant model, P = 0.0005 additive, and P = 0.007 recessive), located in the 3' untranslated region, and an intron 24 SNP (rs1974201: P = 0.004 dominant, P = 0.0005 additive, and P = 0.005 recessive). However, the extensively studied K121Q variant (rs1044498) did not reveal evidence for association with type 2 diabetic ESRD in this African-American population. CONCLUSIONS: This study was the first to comprehensively evaluate variants of the ENPP1 gene for association in an African-American population with type 2 diabetes and ESRD and suggests that variants in the distal region of the ENPP1 gene may contribute to diabetes or diabetic nephropathy susceptibility in African Americans.
OBJECTIVE: Variants in the ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) gene have shown positive associations with diabetes and related phenotypes, including insulin resistance, metabolic syndrome, and type 1 diabetic nephropathy. Additionally, evidence for linkage for type 2 diabetes in African Americans was observed at 6q24-27, with the proximal edge of the peak encompassing the ENPP1 gene. Our objective was to comprehensively evaluate variants in ENPP1 for association with type 2 diabetic end-stage renal disease (ESRD). RESEARCH DESIGN AND METHODS: Forty-nine single nucleotide polymorphisms (SNPs) located in the coding and flanking regions of ENPP1 were genotyped in 577 African-American individuals with type 2 diabetic ESRD and 596 African-American control subjects. Haplotypic association and genotypic association for the dominant, additive, and recessive models were tested by calculating a chi(2) statistic and corresponding P value. RESULTS: Nine SNPs showed nominal evidence for association (P < 0.05) with type 2 diabetic ESRD in one or more genotypic model. The most significant associations were observed with rs7754586 (P = 0.003 dominant model, P = 0.0005 additive, and P = 0.007 recessive), located in the 3' untranslated region, and an intron 24 SNP (rs1974201: P = 0.004 dominant, P = 0.0005 additive, and P = 0.005 recessive). However, the extensively studied K121Q variant (rs1044498) did not reveal evidence for association with type 2 diabetic ESRD in this African-American population. CONCLUSIONS: This study was the first to comprehensively evaluate variants of the ENPP1 gene for association in an African-American population with type 2 diabetes and ESRD and suggests that variants in the distal region of the ENPP1 gene may contribute to diabetes or diabetic nephropathy susceptibility in African Americans.
Authors: Barry I Freedman; Pamela J Hicks; Meredith A Bostrom; Mary E Comeau; Jasmin Divers; Anthony J Bleyer; Jeffrey B Kopp; Cheryl A Winkler; George W Nelson; Carl D Langefeld; Donald W Bowden Journal: Nephrol Dial Transplant Date: 2009-06-30 Impact factor: 5.992
Authors: Barry I Freedman; Jeffrey C Edberg; Mary E Comeau; Mariana Murea; Donald W Bowden; Jasmin Divers; Graciela S Alarcón; Elizabeth E Brown; Gerald McGwin; Jeffrey B Kopp; Cheryl A Winkler; George W Nelson; Gabor Illei; Michelle Petri; Rosalind Ramsey-Goldman; John D Reveille; Luis M Vilá; Carl D Langefeld; Robert P Kimberly Journal: Am J Nephrol Date: 2010-06-07 Impact factor: 3.754
Authors: Meredith A Bostrom; Pamela J Hicks; Lingyi Lu; Carl D Langefeld; Barry I Freedman; Donald W Bowden Journal: Nephrol Dial Transplant Date: 2010-04-22 Impact factor: 5.992
Authors: Barry I Freedman; Pamela J Hicks; Meredith A Bostrom; Mary E Cunningham; Yongmei Liu; Jasmin Divers; Jeffrey B Kopp; Cheryl A Winkler; George W Nelson; Carl D Langefeld; Donald W Bowden Journal: Kidney Int Date: 2009-01-28 Impact factor: 10.612
Authors: Jun Ma; Meijian Guan; Donald W Bowden; Maggie C Y Ng; Pamela J Hicks; Janice P Lea; Lijun Ma; Chuan Gao; Nicholette D Palmer; Barry I Freedman Journal: Clin J Am Soc Nephrol Date: 2016-05-19 Impact factor: 8.237
Authors: Pamela J Hicks; Jennifer L Staten; Nicholette D Palmer; Carl D Langefeld; Julie T Ziegler; Keith L Keene; Michele M Sale; Donald W Bowden; Barry I Freedman Journal: Am J Nephrol Date: 2008-06-26 Impact factor: 3.754
Authors: Sinan Tanyolaç; Andrew A Bremer; Uğur Hodoglugil; Irina Movsesyan; Clive R Pullinger; Steven W Heiner; Mary J Malloy; John P Kane; Ira D Goldfine Journal: Metab Syndr Relat Disord Date: 2009-12 Impact factor: 1.894
Authors: David J Friedman; Matthew E Talbert; Donald W Bowden; Barry I Freedman; Yves Mukanya; Keiichi Enjyoji; Simon C Robson Journal: Diabetes Date: 2008-12-18 Impact factor: 9.461